1353P Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations

SBRT group had a significantly longer median PFS1 than the delayed SBRT group (30.0 months vs. 9.0 months, P＜0.001).The median PFS2 in the early SBRT and delayed SBRT groups were 42.0 and 33.0 months, respectively (P ¼ 0.521).The median OS of both groups has not been reached.No severe toxicities (grade 3) were recorded. Conclusions:Early SBRT to the primary lung lesion significantly improved PFS and is a new potentially effective and tolerable treatment option for patients with advanced NSCLC who had stable disease during first-line EGFR-TKIs treatment.